Klausen Mette Kruse, Knudsen Gitte Moos, Vilsbøll Tina, Fink-Jensen Anders
Psychiatric Centre Copenhagen, Mental Health Services in the Capitol Region of Denmark, Copenhagen University Hospital Frederiksberg, Frederiksberg, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Basic Clin Pharmacol Toxicol. 2025 Mar;136(3):e70004. doi: 10.1111/bcpt.70004.
In the search for novel treatment strategies for alcohol use disorder (AUD), glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) approved for treating Type 2 diabetes and obesity have caught much attention. GLP-1 is a naturally occurring peptide produced in the small intestines and the brain, regulating plasma glucose levels and satiety. This focused review will report on the preclinical studies, case stories, register-based cohort studies, brain-imaging data and secondary analysis of clinical data supporting the role of GLP-1RAs as a novel treatment of AUD. Several clinical trials are ongoing, examining the potential effects of the GLP-1RA semaglutide in AUD.
在寻找酒精使用障碍（AUD）的新型治疗策略过程中，已被批准用于治疗2型糖尿病和肥胖症的胰高血糖素样肽-1（GLP-1）受体激动剂（GLP-1RAs）备受关注。GLP-1是一种在小肠和大脑中天然产生的肽，可调节血糖水平和饱腹感。本综述将报告临床前研究、病例报道、基于登记的队列研究、脑成像数据以及支持GLP-1RAs作为AUD新型治疗方法作用的临床数据二次分析。多项临床试验正在进行中，以研究GLP-1RA司美格鲁肽在AUD中的潜在作用。
